

MEDICAL POLICY

MEDICAL POLICY DETAILS	
Medical Policy Title	Magnetic Resonance Imaging (MRI) of the Breast
Policy Number	6.01.35
Category	Technology Assessment
Original Effective Date	08/18/05
Committee Approval Date	06/15/06, 07/19/07, 08/16/07, 06/19/08, 01/21/10, 05/19/11, 06/21/12, 08/15/13, 06/19/14, 06/18/15, 03/17/16, 3/20/17, 06/21/18, 06/20/19, 05/21/20, 06/17/21, 06/16/22, 09/15/22
Current Effective Date	09/15/22
Archived Date	N/A
Archive Review Date	N/A
Product Disclaimer	• If a product excludes coverage for a service, it is not covered, and medical policy criteria do not apply. • If a commercial product (including an Essential Plan or Child Health Plus product), medical policy criteria apply to the benefit. • If a Medicaid product covers a specific service, and there are no New York State Medicaid guidelines (eMedNY) criteria, medical policy criteria apply to the benefit. • If a Medicare product (including Medicare HMO-Dual Special Needs Program (DSNP) product) covers a specific service, and there is no national or local Medicare coverage decision for the service, medical policy criteria apply to the benefit. • If a Medicare HMO-Dual Special Needs Program (DSNP) product DOES NOT cover a specific service please refer to the Medicaid Product coverage line.

POLICY STATEMENT

- I. Based upon our criteria and assessment of the peer-reviewed literature, magnetic resonance imaging (MRI) has been medically proven to be effective and, therefore, is considered **medically appropriate** for the following breast indications:
- A. In patients with breast augmentation, breast implants (saline or silicone), breast reconstruction, free injection, and capsular contracture to confirm rupture of breast implants, when necessary, in patients when mammography or ultrasound is nondiagnostic of rupture.
- B. Indeterminate breast imaging when mammography or ultrasound is inconclusive and:
1. The finding is not a palpable mass; or
 2. Discordance between imaging findings and core needle biopsy findings (the biopsy result does not adequately explain the abnormal findings on mammogram and/or ultrasound);
 3. Discordance between the imaging findings and histopathologic core need biopsy result, before consideration for surgical management versus observation.
 4. Inconclusive findings of fat necrosis post lumpectomy or mastectomy with or without reconstruction.
 5. There is pathologic nipple discharge (e.g., unilateral, bloody or serous, arising from a single duct, persistent, and spontaneous).
- C. For patients with new diagnosis of breast cancer, including patients with high risk of breast cancer based on the diagnosis of Lobular Carcinoma In Situ (LCIS) or Ductal Carcinoma In Situ (DCIS).
- D. Initial work-up/staging for the following indications:

Medical Policy: MAGNETIC RESONANCE IMAGING (MRI) OF THE BREAST

Policy Number: 6.01.35

Page: 2 of 9

1. Newly diagnosed biopsy proven invasive breast cancer or carcinoma in-situ or adenocarcinoma in axillary lymph node;
 2. Multifocal or multicentric breast cancer;
 3. Before neoadjuvant systemic therapy;
 4. Invasive lobular carcinoma; or
 5. Paget's disease of the breast.
- E. Preoperatively, to establish extent of disease where a diagnosis of malignant phyllode tumor has previously been established by tissue diagnosis.
- F. To determine subsequent treatment strategies in patients with breast cancer; recurrence (e.g., follow-up, recurrence, surveillance):
1. To detect local tumor recurrence in breast cancer patients who have undergone mastectomy and breast reconstruction with an implant or tissue transfer flaps (rectus, latissimus dorsi, or gluteal) for indeterminate breast imaging when mammography or ultrasound is inconclusive or conflict with physical examination or other clinical indicators.
 2. To assess residual tumor in patients who have undergone lumpectomy and have close or positive margins, when the findings may indicate a significant change in surgical management;
 3. To evaluate clinical suspicion of recurrence, following evaluations with mammography and/or ultrasound, if those evaluations are inconclusive or conflict with physical examination or other clinical indicators. This applies to intact breasts, reconstructed breasts, and possible chest wall recurrences following mastectomy;
 4. When there are architectural changes in the breast post-surgery/post-radiation therapy precluding adequate interpretation of conventional mammography and making it difficult to view the entire breast tissue.
 5. When there are equivocal or occult findings (inconclusive or conflicting findings on mammography or ultrasound of a finding that is not a discrete palpable mass); or
 6. Where there are high-risk histologies such as atypical ductal hyperplasia (ADH) or atypical lobular hyperplasia (ALH) or (LCIS).
- G. Restaging/Recurrence:
1. After completion of chemotherapy to evaluate response prior to surgery;
 2. Biopsy proven local recurrence;
 3. Suspicion of recurrence with inconclusive mammogram and/or ultrasound (BIRADS 0); or
 4. Mammogram and ultrasound conflicts with physical exam.
- H. Follow-up/Surveillance of women with prior breast cancer **and one** of the following:
1. Positive for a known high risk genetic breast cancer mutation (e.g., TP53, BRCA 1/2, STK11/LKB1, PTEN, CDHA, NFA, PALB2, ATM, CHEK2, NBN and diagnosed with breast cancer at less than 50 years);
 2. Lifetime risk of a breast cancer (prior to their diagnosis) greater than 20 percent using genetic or clinical risk estimator, calculated prior to the initial diagnosis of breast cancer;
 3. Diagnosis of cancer in both breasts; or two cancers diagnosed in the same breast; or the primary breast cancer was mammographically occult;
 4. Diagnosis of breast cancer at age 50 years or younger; or
 5. Personal history of breast cancer and extremely dense breast tissue (e.g., Category D) on mammography.
- I. When an MRI-guided biopsy is necessary for a lesion related to the above breast indications.
- J. Screening:
1. To screen patients with high genetic risk of breast cancer defined as having any of the following:
 - a. Patient has a confirmed BRCA1 or BRCA2 gene mutation;
 - b. Patient has a first-degree relative who is a confirmed carrier of the BRCA1 or BRCA2 gene mutation even if patient has not been tested for BRCA mutation (if patient has been tested and is negative for mutation, then annual screening is not indicated);
 - c. Patient is a confirmed carrier of ATM, BARD1, CDH1, CHEK2, NBN, NF1, PALB2, or STK11(LKB1) gene mutation;

Medical Policy: MAGNETIC RESONANCE IMAGING (MRI) OF THE BREAST

Policy Number: 6.01.35

Page: 3 of 9

- d. Patient has a first- or second-degree male relative (father, brother, uncle, grandfather) diagnosed with breast cancer;
 - e. Patient is at high risk (lifetime risk about 20% to 25% or greater) of developing breast cancer, as identified by models that are largely defined by family history;
 - f. Patient has one first-degree relative with two primary breast cancers, bilateral breast cancer or both breast and ovarian cancer;
 - g. Patient has two or more first-degree relatives with breast cancer or ovarian cancer;
 - h. Patient has one first-degree relative with breast cancer or ovarian cancer that was diagnosed at age 50 years or less;
 - i. Patient carries or has a first-degree relative who carries a genetic mutation in the TP53 or PTEN genes (Li-Fraumeni syndrome and Cowden and Bannayan-Riley-Ruvalcaba syndromes); or
 - j. As a follow-up MRI in six months for patients with a probable benign and nonspecific, equivocal or uncertain lesion on MRI; or
 2. History of radiation therapy to the chest between the ages of 10 and 30.
- II. Based on our criteria and assessment of the peer-reviewed literature, MRI of the breast has not been medically proven to be effective and, therefore, is considered **investigational** for indications including, but not limited to, the following:
- A. Screening for the detection of breast cancer when the sensitivity of mammography is limited (e.g., dense breasts, breast implants). Breast ultrasound should be considered before MRI for this population of women.
 - B. Screening in average-risk patients (15-20% lifetime risk based on one of the accepted risk assessment tools that utilize family history and other factors).
 - C. Screening in individuals with MSH2, MLH1, MSH6, PMS2, EPCAM, RAD51C, genetic variants of unknown significance, genetic variants favoring polymorphism, or genetic variants of moderate penetrance.
 - D. For further evaluation of an otherwise suspicious breast lesion.
 - E. For further evaluation of low-suspicion findings on conventional testing not indicated for immediate biopsy and referred for short-interval follow-up.
 - F. To evaluate breasts before biopsy in an effort to reduce the number of surgical biopsies for benign lesions.
 - G. To confirm silent/asymptomatic rupture of silicone/saline implants.
 - H. To differentiate benign from malignant breast disease, especially clustered microcalcifications.
 - I. To diagnose a suspicious breast lesion in order to avoid biopsy.
 - J. For routine surveillance following bilateral mastectomy.
- III. Use of computer-aided detection (CAD) is considered inclusive when performed as part of the Breast MRI.
- IV. 3D Imaging is considered inclusive when performed as part of the Breast MRI.

Refer to Corporate Medical Policy # 2.02.06 Genetic Testing for Hereditary BRCA Mutation.

Refer to Corporate Medical Policy # 2.02.44 Genetic Testing for Susceptibility to Hereditary Cancers

Refer to Corporate Medical Policy #11.01.03 Experimental or Investigational Services.

Refer to Corporate Medical Policy #11.01.10 Clinical Trials.

POLICY GUIDELINES

- I. The National Comprehensive Cancer Network (NCCN) Guidelines for Genetic Familial High Risk Assessment for Breast, Ovarian, and Pancreatic Cancer (V2.2022) recommend MRI screening to begin at age 20 years in individuals with Li-Fraumeni Syndrome (TP53 gene mutation) or at the age of the earliest diagnosed breast cancer in the family, which ever comes first.
- II. The NCCN Guidelines for Genetic Familial High Risk Assessment for Breast, Ovarian, and Pancreatic Cancer (V2.2022) recommend MRI screening to begin at age 25 years in individuals with a positive BRCA 1 or BRCA 2 gene mutation or Peutz-Jehgers Syndrome (STK11 gene variations).

Medical Policy: MAGNETIC RESONANCE IMAGING (MRI) OF THE BREAST

Policy Number: 6.01.35

Page: 4 of 9

- III. The NCCN Guidelines for Genetic Familial High Risk Assessment for Breast, Ovarian, and Pancreatic Cancer (V2.2022) recommend MRI screening to begin at age 30 years in individuals with Cowden Syndrome (PTEN Mutation), CDH1, NF1, or PALB2 gene mutations.
- IV. The NCCN Guidelines for Genetic Familial High Risk Assessment for Breast, Ovarian, and Pancreatic Cancer (V2.2022) recommend MRI screening to begin at age 40 years in individuals with a relative diagnosed with breast cancer, or 10 years before the age of the relative when first diagnosed with breast cancer, but not prior to age 25.
- V. To confirm breast implant rupture in symptomatic patients where ultrasound findings suggest rupture, documentation of the medical necessity of MRI imaging is required.

DESCRIPTION

Magnetic resonance imaging (MRI) is a diagnostic imaging modality that uses magnetic and radio frequency fields to produce a non-invasive, two-dimensional view of an internal organ or structure. Through radiofrequency emissions, a tomographic image can be constructed that will represent the tissue being analyzed and the environment surrounding it. MRI is designed to identify anatomical abnormalities and to provide information on characteristics of the tissue. Breast MRI generally requires a high field strength system and a dedicated breast surface coil.

Computer-Aided Detection (CAD) for MRI (also referred to as computer-aided evaluation or CAE), unlike CAD systems used with mammography, is not aimed primarily at identifying lesions for consideration by a radiologist. CAD systems for MRI propose to provide easier ways of interpreting the patterns of contrast enhancement and washout across a series of images, which may help identify lesions and their likelihood of being malignant.

Lesions on mammography have a subtle appearance. However, most cancers enhance on MRI. The challenge is determining which lesions are benign and which are malignant. A large number of images are produced during MRI of the breast. Images are taken at varying depths throughout each breast, multiplied by the number of times the breast is imaged to capture different time points in the enhancement process, which can produce hundreds of images. Radiologists view the images to detect suspicious areas, and then may choose a region of interest and look at the enhancement pattern; however, there may be variations across radiologists in the regions of interest selected and in the precise definition of the region of interest. CAE systems use color-coding and differences in hue to indicate the patterns of enhancement for each pixel in the breast image, which may allow radiologists to analyze the enhancement patterns systematically.

RATIONALE

A number of magnetic resonance scanners have received 510(k) premarket clearance by the U.S. Food and Drug Administration (FDA) Center for Devices and Radiological Health (CDRH) for use in the United States. Low-field MRI systems have also received 510(k) premarket clearance by the FDA CDRH, such as the ARTOSCAN (0.2 Tesla magnet) and MAGNA SL (0.3 Tesla magnet). Specialized breast coils such as the OBC-300 Breast Array Coil (MRI Devices Corp., Waukesha, WI) and MR-compatible equipment for performing biopsy have received FDA 510(k) clearance. Computer-aided detection (CAD) systems for use with MRI of the breast have received 510(k) marketing clearance from the FDA, e.g., CADstream (Conforma, Kirkland, WA) and 3TP Software Option (CAD Sciences, White Plains, NY).

Safety Alert: On May 10, 2005, the FDA issued a Public Health Notification reminding radiology personnel and physicians that serious injury or death can occur when patients with implanted neurological stimulators undergo MRI procedures, even if the device has been turned off.

MRI before and after neoadjuvant chemotherapy to guide decisions to use breast conservation therapy (BCT). Available studies consistently show that breast MRI appears to be better than conventional presurgical clinical staging methods at determining extent and size of residual tumor. Compared with histopathology, the reference standard, MRI demonstrated the presence of residual tumor with estimated sensitivity ranging from 90-100% and specificity from 50-100%. MRI estimated the size and extent of tumor correctly in comparison with pathologic evaluation in 57%-97% of cases among five studies. As MRI appears to provide a more accurate determination of tumor size and extent compared with clinical staging, it is likely that MRI would be more accurate in determining eligibility for BCT. Using staging results instead of

Medical Policy: MAGNETIC RESONANCE IMAGING (MRI) OF THE BREAST

Policy Number: 6.01.35

Page: 5 of 9

clinical staging for presurgical planning would lead to an improvement in net health outcome by increasing the use of BCT when appropriate and avoiding the need for re-excision surgery when BCT is not appropriate.

A prospective study of 118 women evaluated the accuracy of contrast-enhanced MRI (CE-MRI) mammography for depiction of synchronous contralateral breast cancer in patients with newly diagnosed unilateral breast cancer or high-risk lesions, with histologic analysis or follow-up as a reference. Patients had negative findings in the contralateral breast at physical examination, ultrasound and conventional mammography. CE-MRI showed contralateral lesions in 28 (24%) of 118 patients. Twenty-four of the 28 lesions were detected in patients with dense breasts (BI-RADS breast density category 3 or 4). At histologic analysis, 22 lesions were confirmed as malignant; six were fibroadenomas.

MRI for early prediction of response to neoadjuvant chemotherapy. There is insufficient evidence to permit conclusions on the effect on health outcomes of using breast MRI to provide an early prediction of the response to neoadjuvant chemotherapy. Available evidence is limited to a few small studies with inconsistencies in outcome measures, reporting, and use of statistical comparison. Results are not consistent.

MRI for patients with personal history of breast cancer. Current studies are small and retrospective but suggest some benefit for surveillance MRI after breast cancer treatment. Although MRI may demonstrate new or recurrent cancers earlier than routine mammographic and/or ultrasonographic imaging, the low yield may not be cost-effective in counterbalancing its inherent low specificity and subsequent need for additional imaging and/or tissue biopsy. Many of the articles indicate that prospective studies are necessary to determine which subset of patients, if any, may benefit from MRI surveillance in the setting of previous breast cancer, and whether this early identification translates to improved disease-specific survival.

MRI for screening high genetic-risk patients. Asymptomatic women thought to be at high risk of breast cancer due to genetic risk have a lifetime risk of cancer that is much higher than average. In addition, breast cancer often occurs at a much younger age than average. Traditional screening using mammography is thought to be less sensitive in younger versus older women because of a higher prevalence of dense breast tissue. Clinical evidence shows at least equivalent performance for MRI in terms of sensitivity in detecting breast cancer, compared to mammography. In two published studies, MRI detected 100% of cancer cases, while mammography detected 33%. In one study, the difference between MRI and mammography sensitivity was statistically significant, but not in the other. Presently, there are no studies that adequately define the age of initiation or the appropriate frequency of testing with MRI in high-risk women. The American Cancer Society (ACS) recommends annual screening with MRI as an adjunct to mammography for those at high risk for breast cancer (lifetime risk of 20-25% or greater), for those who received radiation to the chest between 10 to 30 years of age, for those with Li-Fraumeni syndrome and first-degree relatives, and for those with Cowden and Bannayan-Rile-Ruvalcaba syndromes and first-degree relatives. The ACS states that there is insufficient evidence to recommend for or against annual MRI screening for those with a lifetime risk for breast cancer of 15-20%, lobular carcinoma in situ (LCIS) or atypical lobular hyperplasia (ALH), atypical ductal hyperplasia (ADH), heterogeneously or extremely dense breast on mammography, or a personal history of breast cancer, including ductal carcinoma in situ (DCIS). The ACS recommends against annual MRI screening for those with a less than 15% lifetime risk of breast cancer.

Lifetime risk of breast cancer may be calculated using the Gail, Claus or the Tyrer-Cuzick model. The Gail model bases its risk estimates on personal risk factors such as current age, age at menarche (first menstrual period), and history of prior breast biopsies, along with any history of breast cancer in first-degree relatives. The Claus model estimates risk based on family history of breast cancer in both first- and second-degree relatives. The Tyrer-Cuzick model takes into account the person's history (age, extended family history of breast and ovarian cancer, childbirth history, history of breast biopsy and its pathology, age of menarche and menopause, exposure to post-menopausal hormones, and Ashkenazi Jewish heritage), as well as the person's height/weight (higher BMI-body mass index=increased risk). These two models could easily give different estimates using the same data. Results from any of the risk assessment tools should be discussed by a patient and doctor when being used to decide whether to start MRI screening.

The American College of Radiology Appropriateness Criteria for Breast Cancer Screening (2017) considers MRI for screening high-risk women, including women with a BRCA gene mutation and their untested first-degree relatives, women with a history of chest irradiation between 10 to 30 years of age, and women with 20% or greater lifetime risk of breast cancer, usually appropriate.

Medical Policy: MAGNETIC RESONANCE IMAGING (MRI) OF THE BREAST

Policy Number: 6.01.35

Page: 6 of 9

MRI screening for detection of breast cancer in patients who have breast characteristics limiting the sensitivity of mammography. The American College of Radiology Appropriateness Criteria for Breast Cancer Screening (2017) has indicated that MRI screening may be appropriate for intermediate-risk women, including women with a history of breast cancer, lobular neoplasia, or atypical ductal hyperplasia, or a 15% to 20% lifetime risk of breast cancer.

MRI screening for average-risk patients. Evidence for routine use of MRI in breast cancer screening is limited to studies that compare the sensitivity and specificity of MRI screening to other methods, such as mammography. Such evidence is limited because it does not evaluate the impact on patient outcomes. The American College of Radiology Appropriateness Criteria for Breast Cancer Screening (2017) considers MRI for screening average-risk women with less than 15% lifetime risk of breast cancer usually not appropriate.

Computer-aided detection (CAD) with MRI/computer-aided evaluation (CAE). There is insufficient evidence to assess whether the use of CAD with MRI of the breast improves intermediate and long-term outcomes. There are no high-quality published studies of the impact of commercially available CAD systems on the sensitivity and specificity of MRI of the breast. Literature is not clear on how CAD systems are to be used. Because CAD is not 100% sensitive, potentially malignant lesions detected on original films are followed up, as well as additional lesions identified by CAD that the radiologist determines should be worked up. In this way, CAD can add to the sensitivity but not the specificity of MRI. With MRI of the breast, the issue is trying to increase the specificity, not the sensitivity, which is already high. Additionally, there is insufficient evidence to assess whether the use of CAD systems would maintain or increase the sensitivity, specificity and recall rates of breast MRI used to screen women at high genetic risk of breast cancer.

Prospective, well-designed, and executed studies that look specifically at the addition of CAD with MRI are needed to determine whether or not the use of CAD provides a positive clinical benefit to patients. Small studies propose the use of CAD to identify lesions that would not need to be biopsied. However, there were false negative findings. The risk of missing cancers and delaying treatment has to be weighed against the opportunity for reducing the number of unnecessary biopsies. The magnitude of this risk cannot be estimated reliably from available studies. Further research is needed that focuses on the incremental value of CAD in large samples and in a variety of settings.

CODES

- *Eligibility for reimbursement is based upon the benefits set forth in the member's subscriber contract.*
- *CODES MAY NOT BE COVERED UNDER ALL CIRCUMSTANCES. PLEASE READ THE POLICY AND GUIDELINES STATEMENTS CAREFULLY.*
- *Codes may not be all inclusive as the AMA and CMS code updates may occur more frequently than policy updates.*

CPT Codes

Code	Description
76376	3D rendering with interpretation and reporting of computed tomography, magnetic resonance imaging, ultrasound, or other tomographic modality with image postprocessing under concurrent supervision; not requiring image postprocessing on an independent workstation
76377	requiring image postprocessing on an independent workstation
76498	Unlisted magnetic resonance procedure (e.g., diagnostic, interventional)
77046	Magnetic resonance imaging, breast, without contrast material; unilateral
77047	Magnetic resonance imaging, breast, without contrast material; bilateral
77048	Magnetic resonance imaging, breast, without and with contrast material(s), including computer-aided detection (CAD Real-time lesion detection, characterization and pharmacokinetic analysis), when performed; unilateral

Medical Policy: MAGNETIC RESONANCE IMAGING (MRI) OF THE BREAST**Policy Number: 6.01.35****Page: 7 of 9**

Code	Description
77049	Magnetic resonance imaging, breast, without and with contrast material(s), including computer-aided detection (CAD Real-time lesion detection, characterization and pharmacokinetic analysis), when performed; bilateral

Copyright © 2022 American Medical Association, Chicago, IL

HCPCS Codes

Code	Description
C8903	Magnetic resonance imaging with contrast, breast; unilateral
C8905	Magnetic resonance imaging without contrast followed by with contrast, breast; unilateral
C8906	Magnetic resonance imaging with contrast, breast; bilateral
C8908	Magnetic resonance imaging without contrast followed by with contrast, breast; bilateral
C8937	Computer-aided detection, including computer algorithm analysis of breast MRI image data for lesion detection/characterization, pharmacokinetic analysis, with further physician review for interpretation (list separately in addition to code for primary procedure)

ICD10 Codes

Code	Description
C50.011- C50.929	Malignant neoplasm of breast, female or male (code range)
C79.81	Secondary malignant neoplasm of breast
D05.00-D05.92	Carcinoma in situ of breast (code range)
L59.9	Disorder of the skin and subcutaneous tissue related to radiation, unspecified
N63.0	Unspecified lump in unspecified breast
Z12.39	Encounter for other screening for malignant neoplasm of breast
Z15.01	Genetic susceptibility to malignant neoplasm of breast
Z80.3	Family history of malignant neoplasm of breast
Z85.3	Personal history of malignant neoplasm of breast
Z92.3	Personal history of irradiation

REFERENCES

*Agency for Healthcare Research and Quality (AHRQ). Effectiveness of noninvasive diagnostic tests for breast abnormalities. AHRQ Effective Health Care Program. 2006 Feb. Archived Feb 2012. [<https://effectivehealthcare.ahrq.gov/products/breast-abnormalities-tests-update/research>] accessed 7/22/22.

ACR Appropriateness Criteria Breast Cancer Screening. American College of Radiology. J Am Coll Radiol 2017 Nov;14(11S):S383-S390.

ACR Appropriateness Criteria Breast Cancer Screening in Women at Higher-Than-Average Risk: Recommendations from the ACR. J Am Coll Radiol 2018 Mar;15(3 PTA):408-414.

Medical Policy: MAGNETIC RESONANCE IMAGING (MRI) OF THE BREAST

Policy Number: 6.01.35

Page: 8 of 9

ACR Practice Guideline for the Performance of Contrast-Enhanced Magnetic Resonance Imaging (MRI) of the Breast. American College of Radiology 2004, revised 2018. [<https://www.acr.org/-/media/ACR/Files/Practice-Parameters/mr-contrast-breast.pdf>] accessed 7/22/22.

*American Society of Breast Surgeons. Consensus statement on the use of magnetic resonance imaging in breast oncology. 2007 May 6, revised 2017 Jun 22

[https://www.breastsurgeons.org/new_layout/about/statements/PDF_Statements/MRI.pdf] accessed 7/22/22.

Baltzer PAT, et al. Is breast MRI a helpful additional diagnostic test in suspicious mammographic microcalcifications? Magn Reson Imaging 2018 Feb;46:70-74.

Cheung YC, et al. Preoperative assessment of contrast-enhanced spectral mammography of diagnosed breast cancers after sonographic biopsy: correlation to contrast-enhanced magnetic resonance imaging and 5-year postoperative follow-up. Medicine 2020;99:5(e19024).

*Cho N, et al. Contralateral lesions detected by preoperative MRI in patients with recently diagnosed breast cancer: application of MR CAD in differentiation of benign and malignant lesions. Eur J Radiol 2012;81(7):1520-6.

De Paula IB and Campos AM. Breast imaging in patients with nipple discharge. Radiol Bras 2017 Nov-Dec;50(6):383-388.

*Dietzal M, et al. Association between survival in patients with primary invasive breast cancer and computer aided MRI. J Magn Reson Imaging 2013 Jan;37(1):146-55.

Fueger BJ, et al. Can supplementary contrast-enhanced MRI of the breast avoid needle biopsies in suspicious microcalcifications seen on mammography? A systematic review and meta-analysis. The Breast 2021;56:53-60.

Hernandez ML, et al. Abbreviated magnetic resonance imaging in breast cancer: A systematic review of literature. European Journal of Radiology Open 2021;8:100307.

*Khatcheressian JL, et al. Breast cancer follow-up and management after primary treatment: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 2013; 31(7):961-5.

*Khatcheressian JL, et al. American Society of Clinical Oncology 2006 update of the breast cancer follow-up and management guidelines in the adjuvant setting. J Clin Oncol 2006 Nov 1;24(31):5091.

*Kriege M, et al. Efficacy of MRI and mammography for breast cancer screening in women with a familial or genetic predisposition. NEJM 2004 Jul 29; 351(5):427-37.

Li H, et al. MRI and PET/CT for evaluation of the pathological response to neoadjuvant chemotherapy in breast cancer: a systematic review and meta-analysis. Breast 2018 Aug;40:106-115.

*Medeiros LR, et al. Accuracy of magnetic resonance in suspicious breast lesions: a systematic quantitative review and meta-analysis. Breast Cancer Res Treat 2011 Apr;126(2):273-85.

Monticciolo DL, et al. Breast cancer screening in women at higher-than-average risk: recommendations from the ACR. J Am Coll Radiol 2018;15(3 Pt A):408-414.

*Monticciolo DL. Magnetic resonance imaging of the breast for cancer diagnosis and staging. Semin Ultrasound CT MR 2011 Aug;32(4):319-30.

National Comprehensive Cancer Network. Breast Cancer. NCCN Practice Guidelines in Oncology. V4.2022 [https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf] accessed 7/22/22.

National Comprehensive Cancer Network. Genetic/familial high-risk assessment: breast and ovarian. NCCN Clinical Practice Guidelines in Oncology V2.2022 [https://www.nccn.org/professionals/physician_gls/pdf/genetics_bop.pdf] accessed 7/22/22.

Park J, et al. Comparison of mammography, digital breast tomosynthesis, automated breast ultrasound, magnetic resonance imaging in evaluation of residual tumor after neoadjuvant chemotherapy. Eur J Radiol 2018 Nov;108:261-268.

Medical Policy: MAGNETIC RESONANCE IMAGING (MRI) OF THE BREAST

Policy Number: 6.01.35

Page: 9 of 9

Quin Y, et al. Contrast-enhanced spectral mammography: A potential exclusion diagnosis modality in dense breast patients. Cancer Medicine. 2020;00:1–7.

Rahbar H, et al. Utility of diffusion-weighted imaging to decrease unnecessary biopsies prompted by breast MRI: a trial of the ECOG-ACRIN cancer research group. clincancerres.aacrjournals.org 2019 Jan; DOI: 10.1158/1078-0432.CCR-18-2967.

*Sardanelli F, et al. Sensitivity of MRI versus mammography for detecting foci of multifocal, multicentric breast cancer in fatty and dense breasts using the whole-breast pathologic examination as a gold standard. AJR Am J Roentgenol 2004 Oct;183(4):1149-57.

*Saslow D, et al. American Cancer Society Guidelines for Breast Screening with MRI as an Adjunct to Mammography. Cancer 2007;57(2):75-89.

Shergill R, et al. The utility of short-interval follow-up for baseline high-risk screening breast MRI. Can Assoc Radiol J 2020 May;71(2):226-230.

Taydaş O, et al. Comparison of MRI and US in tumor size evaluation of breast cancer patients receiving neoadjuvant chemotherapy. Eur J Breast health 2019;15(2):119-124.

Van Bodegraven EA, et al. Guidelines and recommendations for MRI in breast cancer follow-up: a review. Eur J Obstet Gynecol Reprod Biol 2017 Nov;218:5-11.

Veenhuizen S, et al. Supplemental breast MRI for women with extremely dense breasts: results of the second screening round of the DENSE trial. Radiology 2021; 299:278-286.

Vreeland TJ, et al. Routine pre-treatment MRI for breast cancer in a single-payer medical center: effects on surgical choices, timing and outcomes. J Cancer 2017 Jul 23;8(13):2442-2448.

Vreemann S, et al. The frequency of missed breast cancers in women participating in a high-risk MRI screening program. Breast Cancer Res Treat 2018 Jun;169(2):323-331.

Xiang, W et al. A meta-analysis of contrast-enhanced spectral mammography versus MRI in the diagnosis of breast cancer. Thoracic Cancer 2020;11:1423-1432.

Zhou J, et al. Predicting the response to neoadjuvant chemotherapy for breast cancer: wavelet transforming radiomics in MRI. BMC Cancer 2020;20:100.

*Key Article

KEY WORDS

Breast MRI, CAD MRI.

CMS COVERAGE FOR MEDICARE PRODUCT MEMBERS

There is currently a Local Coverage Determination (LCD) for Breast Imaging: Mammography/Breast Echography (Sonography)/Breast MRI/Dictograph. Please refer to the following LCD website for Medicare Members:

https://www.cms.gov/medicare-coverage-database/details/lcd-details.aspx?LCDId=33585&ver=33&CntrctrSelected=298*1&Cntrctr=298&s=41&DocType=All&bc=AggAAAIAGAA&A&